Target : Multicenter, randomized and open trial evaluating the interest of a dose of prasugrel (Efient®) adapted to thebiological test VerifyNow (monitored arm) in comparison with a fixed dose of prasugrel (conventional arm) inpatients over 75 in need of angioplasty and stenting in order to reduce bleeding, ischemic complications as well as stent thrombosis.

Trial date : 2012

Number of patients : 877

Source of funding : Public (APHP) and private (Eli Lilly, Daiichi-Sankyo, Accriva diagnostics, Medtronic & Stentys)

Centers participating : 35 french centers

N°NCT : NCT01538446

STATUT

Design in Am Heart J. – november 2014

Présentation Hotline ESC2016 – august 2016

Published dans Lancet – august 2016

Press Release APHP-ACTION – august 2016

Article in Medscape – august 2016